DexCom (NASDAQ:DXCM) Insider Kevin Sayer Sells 26,756 Shares

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider owned 328,970 shares in the company, valued at $25,106,990.40. This represents a 7.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $74.85 on Wednesday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The stock has a market capitalization of $28.88 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 1.21 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The company’s 50 day simple moving average is $72.79 and its 200 day simple moving average is $69.01.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company earned $0.32 earnings per share. The company’s quarterly revenue was up 15.0% on a year-over-year basis. As a group, research analysts predict that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after buying an additional 42,411 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after acquiring an additional 516,526 shares in the last quarter. Norges Bank bought a new stake in shares of DexCom during the fourth quarter valued at approximately $483,356,000. Invesco Ltd. raised its position in shares of DexCom by 14.8% during the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock worth $352,781,000 after purchasing an additional 686,228 shares during the period. Finally, CIBC Private Wealth Group LLC raised its position in shares of DexCom by 7.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after purchasing an additional 220,313 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Stifel Nicolaus set a $90.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, June 5th. Citigroup restated a “buy” rating and issued a $84.00 price target (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a research note on Tuesday, June 23rd. They set a “buy” rating and a $86.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.40.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.